Technology & Telecommunication Services » Software | RaySearch Laboratories AB

RaySearch Laboratories AB Series B | Balance Sheet

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
38,231.00
56,085.00
59,705.00
87,720.00
104,156.00
112
Total Accounts Receivable
81,676.00
147,938.00
171,460.00
333,702.00
419,024.00
459
Inventories
-
-
-
-
33.00
10
Other Current Assets
6,607.00
8,698.00
16,394.00
14,167.00
20,675.00
23
Total Current Assets
126,514.00
212,721.00
247,559.00
435,589.00
543,888.00
604
Net Property, Plant & Equipment
5,567.00
12,951.00
41,760.00
35,667.00
36,114.00
93
Long-Term Note Receivable
-
-
-
2,267.00
11,684.00
23
Intangible Assets
166,678.00
164,081.00
195,114.00
243,219.00
322,598.00
377
Total Assets
299,162.00
389,753.00
484,490.00
717,254.00
915,064.00
1,105
ST Debt & Current Portion LT Debt
-
-
-
-
74,033.00
Accounts Payable
6,925.00
9,034.00
9,514.00
11,943.00
27,403.00
Income Tax Payable
5,883.00
5,666.00
5,855.00
11,148.00
15,945.00
Other Current Liabilities
31,134.00
41,685.00
60,091.00
101,847.00
115,083.00
Total Current Liabilities
43,942.00
56,385.00
75,460.00
124,938.00
232,464.00
Long-Term Debt
-
29,243.00
38,164.00
61,527.00
9,751.00
Provision for Risks & Charges
21,950.00
-
-
-
-
Deferred Taxes
36,266.00
40,724.00
51,292.00
70,089.00
91,644.00
Other Liabilities
-
11,853.00
-
-
-
Total Liabilities
102,561.00
138,205.00
164,973.00
257,066.00
334,639.00
Common Equity (Total)
196,601.00
251,548.00
319,517.00
460,188.00
580,425.00
Total Shareholders' Equity
196,601.00
251,548.00
319,517.00
460,188.00
580,425.00
Total Equity
196,601.00
251,548.00
319,517.00
460,188.00
580,425.00
Liabilities & Shareholders' Equity
299,162.00
389,753.00
484,490.00
717,254.00
915,064.00

About RaySearch Laboratories AB

View Profile
Address
Sveavägen 44
Stockholm AB 103 65
Sweden
Employees -
Website http://www.raysearchlabs.com
Updated 07/08/2019
RaySearch Laboratories AB engages in the development of software solutions for improved radiation therapy of cancer. It operates through the following geographical segments: Sweden, North America, Asia, and Europe and the rest of the World. Its products and services are divided into three categories: RayStation, Partner Products, and Research.